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Abstract
Vascular disrupting agents (VDAs), anti-cancer drugs that target established tumor blood vessels, fall into two main classes:
microtubule targeting drugs, exemplified by combretastatin A4 (CA4), and flavonoids, exemplified by 5,6-dimethylxanthe-
none-4-acetic acid (DMXAA). Both classes increase permeability of tumor vasculature in mouse models, and DMXAA in
particular can cause massive tumor necrosis. The molecular target of CA4 is clearly microtubules. The molecular target(s) of
DMXAA remains unclear. It is thought to promote inflammatory signaling in leukocytes, and has been assumed to not target
microtubules, though it is not clear from the literature how carefully this assumption has been tested. An earlier flavone
analog, flavone acetic acid, was reported to promote mitotic arrest suggesting flavones might possess anti-microtubule
activity, and endothelial cells are sensitive to even mild disruption of microtubules. We carefully investigated whether
DMXAA directly affects the microtubule or actin cytoskeletons of endothelial cells by comparing effects of CA4 and DMXAA
on human umbilical vein endothelial cells (HUVEC) using time-lapse imaging and assays for cytoskeleton integrity. CA4
caused retraction of the cell margin, mitotic arrest and microtubule depolymerization, while DMXAA, up to 500 mM, showed
none of these effects. DMXAA also had no effect on pure tubulin nucleation and polymerization, unlike CA4. We conclude
that DMXAA exhibits no direct anti-microtubule action and thus cleanly differs from CA4 in its mechanism of action at the
molecular level.
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Introduction
Tumor vasculature has been attractive target for chemothera-
peutic drug since it is fundamental in tumor growth, progression
and metastasis. As cancer cells proliferate, their demand for
nutrients and oxygen increases. To recruit new blood vessels to the
growing tumor, cancer cells secrete various angiogenic factors [1].
In 1972, Folkman’s group showed that tumor cells implanted into
the avascular cornea of rabbit eye recruited new blood vessels [2,3]
and hypothesized that blocking angiogenesis with a drug would
prevent tumor growth and in some cases cause tumor regression.
An angiogenesis-blocking antibody, Avastin, is now widely used in
combination with cytotoxic drugs to treat tumors, and other anti-
angiogenesis drugs are in different stages of development [4].
Vascular disrupting agents (VDAs) present an alternative way to
target tumor blood vessels. Unlike anti-angiogenic drugs, VDAs
damage established tumor blood vessels. In rodent cancer models,
VDAs cause rapid shutdown of blood flow in established solid
tumors in minutes, resulting in massive hemorrhagic necrosis in
tumors [5,6]. Remarkably, vasculature outside of the tumor is not
damaged, though the molecular or anatomic basis of this
differential sensitivity remains unclear.
Current investigational VDAs can be divided into two major
groups, microtubule binding agents and flavonoids. Combretasta-
tin A4 (CA4) is the furthest-developed tubulin binding VDA. It
binds to the colchicine binding site in tubulin and depolymerizes
microtubules, but is less toxic than colchicine [7]. The first anti-
cancer flavonoid, FAA, was originally identified by the De-
velopmental Therapeutic Program, Division of Cancer Treat-
ment, NCI as an antitumor agent in mice [8]. FAA had little
activity in humans. Baguley and colleagues identified DMXAA as
a more potent derivative [9]. Currently, CA4 and related
compounds are in phase I/II/III clinical trials DMXAA is in
phase III trials in both cases for treatment of intractable cancers in
combination with standard chemotherapy [10,11,12]. So far,
DMXAA has not exhibited the high anti-tumor efficacy in humans
that was seen in mouse models, but it remains a conceptually
exciting drug.
Despite promising results in rodent models, and some evidence
of clinical efficacy, the molecular, cellular and tissue mechanisms
of VDAs remain poorly understood. This lack of mechanistic
understanding has hindered clinical development, making it hard
to develop predictive or response biomarkers, or in the case of
DMXAA, more potent derivatives. CA4 clearly targets micro-
tubules and reorganizes actin cytoskeleton resulting membrane
blebbing [13,14,15], but how this leads to vascular permeabiliza-
tion, and why this effect is tumor-selective, remain unclear.
DMXAA is known to stimulate white blood cells to secrete various
cytokines in mouse by an unknown pathway that requires the
kinase TBK1 (TANK binding kinase 1) activity [16]. Tumor
necrosis factor-alpha (TNF-alpha) secretion seems important for
DMXAA action in vivo, since its anti-tumor activity was impaired,
though not completely lost, in TNF-alpha receptor knock-out mice
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hyper-permeability appears to be indirect, via leukocyte-mediated
signaling. However, DMXAA has been reported to directly trigger
signaling changes and apoptosis in endothelial cells [19] and
endothelial barrier function is exquisitely sensitive to microtubule
disruption [20,21,22]. DMXAA is not thought to target micro-
tubules, but to our knowledge this point has not been critically
addressed in the literature. FAA was reported to cause G2/M
arrest at high concentrations [23], suggesting a potential for anti-
microtubule action by the flavonoid class, and tubulin is known to
bind structurally diverse aromatic molecules. In this study, we
critically evaluated whether DMXAA has anti-microtubule
activity in endothelial cells. Our results are negative, and thus
support the widespread assumption that the two VDA classes differ
in mechanism, but we feel this result is nevertheless a useful
contribution to the VDA literature.
Results
To compare the effects of CA4 and DMXAA on endothelial
cells we performed time-lapse imaging of HUVEC cells before
drug, and in drug for 30 min (Fig. 1). Live cell microscopy can
sensitively report effects on cytoskeleton, adhesion, proliferation
and the signaling pathways that control them. CA4 caused rapid
contraction and loss of cell-cell interaction starting within minutes
of drug addition (Fig. 1A middle panel) as previously described
[13]. This response was evident from retraction of cell margins and
formation of thin retraction fibers. Retraction fibers terminated at
the cell body in characteristic phase-dense structures (yellow
arrows), similar to those previously characterized in cells rounding
up for mitosis [24]. DMXAA and none treated control HUVEC
cells showed no signs of retraction (Fig. 1A lower panel and upper
panel). These differential effects on retraction were quantified by
image analysis which revealed time-dependent retraction in CA4
but not DMXAA treated cells (Fig. 1B). Total cell surface area was
decreased about 20% in CA treated cells after 30 min whereas
control and 500 mM of DMXAA had no effect (Fig. 1B).
Microtubule-targeting drugs disrupt mitotic spindle assembly,
leading to activation of the spindle assembly checkpoint and
mitotic arrest [25]. Thus mitotic index and mitosis duration are
sensitive markers of microtubule disruption. Using phase contrast
microscopy, mitotic indices were quantified as previously de-
scribed [26]. As expected, CA4 treated HUVEC cells gradually
accumulated in mitotic arrest, leading to a mitotic index of up to
50% at 12 hours of drug treatment (Fig. 1C and D). They
remained in mitotic arrest for prolonged period, and mostly died
after 12 to 16 hours of arrest (Data not shown), presumably by
activation of the intrinsic apoptosis pathway [27]. DMXAA caused
no increase in mitotic index and it was about the same compared
to vehicle control. At high concentrations of DMXAA, 250 mM
and 500 mM, the fraction of mitotic cells were 1.6% and 1.5%
respectively, which is slightly lower than the control cells without
drug (3.7%), suggesting a mild inhibition of cell cycle progression.
To test directly if DMXAA affects the microtubule or actin
cytoskeleton in endothelial cells, we imaged microtubule and actin
in fixed, drug-treated HUVEC cells by spinning disk microscopy
(Fig. 2). In control cells, microtubule structures radiated out from
the centrosomes and thin actin bundles were visible throughout
the cell (Fig. 2 upper panel, top row of images). CA4 induced dose-
dependent microtubule disruption, starting at 12.5 nM. In cells
treated with this minimal concentration, the remaining micro-
tubules lost their radial structure and were tangled up and around
the centrosome (Fig. 2 lower panel). Actin bundles appeared
thicker and brighter. At 100 nM CA4 microtubules were
completely depolymerized and actin bundles appeared even more
prominent. No changes in microtubules were noted following
DMXAA treatment up to 500 mM (figure 2, upper panel).
The lack of a direct effect of DMXAA on the cytoskeleton of
endothelial cells we observed by immunofluorescence appeared to
contradict literature reports [28,29]. To validate the activity of the
batch of commercial DMXAA we used, we tested its effect on
TNF-alpha secretion by the mouse macrophage like cell line
Raw264.7 (Fig. 3G). Our batch of DMXAA induced TNF-alpha
secretion with a time and dose dependence similar to published
data [30]. Thus our DMXAA batch has the expected activity on
macrophages, and its lack of effects on the endothelial cell
cytoskeleton is likely to be a reliable negative result.
To obtain more quantitative data on possible cytoskeleton
effects of DMXAA, we assayed the fraction of tubulin and actin in
the monomer and polymer pools with a cell permeabilization assay
(Fig. 3). In brief, HUVEC cells were treated with DMXAA at
different concentrations for 30 min, or CA4 for 10 min. We
avoided longer exposure to CA4 since retracted cells tend to lose
substrate attachment during permeabilization. Drug-treated cells
were permeabilized using a non-ionic detergent (triton X-100) in
a microtubule and F-actin stabilizing buffer for 2 min. Unpoly-
merized protein was released into the supernatant and polymer
remained associated with the substrate. Tubulin and actin in both
fractions were quantified by Western blotting. Band intensities
were analyzed using ImageJ and percent of soluble or polymerized
tubulin or actin was plotted over total tubulin or actin (soluble plus
polymerized) (fig. 3A, lower graphs). Without drug, approximately
75% of tubulin was polymerized and 25% was soluble in control
cells (without drug). CA4 caused dose-dependent microtubule
depolymerization with an EC50 of ,5–10 nM (fig. 3A). DMXAA,
in contrast, had no effect on the fraction of polymerized tubulin
(fig. 3B). The fraction of actin in polymerized form reproducibly
increased following CA4 treatment, consistent with the imaging
data (fig. 3A, lower graph). The EC50 value was slightly higher for
actin polymerization than for tubulin depolymerization, suggesting
most microtubules must be depolymerized for the actin cytoskel-
eton to respond.
To test whether microtubule depolymerization is necessary for
CA4 to induce actin polymerization, we pretreated taxol to
prevent microtubule depolymerization (fig. 3 C). Taxol pre-
treatment completely blocked microtubule disruption by CA4.
Interestingly, the response of actin to CA4 was decreased by taxol
pretreatment suggesting microtubule disruption is required for
actin polymerization by CA4. Then we checked other microtubule
targeting drugs to check whether this effect was specific to CA4
(Fig. 3D). We compared nocodazole, colcemid, vinblastine and
podophyllotoxin to disrupt microtubules and taxol to stabilized
microtubules. All the depolymerizer decreased the amount of
insoluble tubulin as expected. However, we the increase in actin
polymerization was unique to CA4 compared to any other
microtubule disrupting drug. Only the microtubule stabilizing
drug taxol clearly increased polymerized actin. These data
suggested that CA4 has an effect on microtubules that differs,
perhaps in subtle ways, from other depolymerizers. For example, it
might partially stabilize microtubules at threshold concentrations.
Its induction of actin polymerization was presumably indirect via
the Rho GTPase pathway as reported [13]. On the other hand,
DMXAA caused a slight decrease in actin polymerization at the
highest concentrations, so its effects on the endothelial cell
cytoskeleton were, if anything, opposite to those of CA4 (Fig. 3B).
Lastly, we checked post translational modification of tubulin such
as acetylation and detyrosination (fig. 3E). Consistent with
permeabilization assay, there were no changes in acetylated or
Vascular Disrupting Agents Effect on Cytoskeleton
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40177Figure 1. DMXAA does not induce any morphological changes in HUVEC cells whereas CA4 treated cells immediately contract. (A)
Images were collected from phase contrast time-lapse movies at indicated times. Original time-lapse imaging was taken every 30 sec for an hour in
the presence of 500 mM of DMXAA, 100 nM of CA4 or without drug (control). Elapsed time indicated in hours:minutes. (B) Cell edges were drawn to
measure the number of pixels within the cell edges. Individual cell areas were summed to measure total cell surface area at each time point. The total
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acetylation clearly decreased in CA4 treated cells. Detyrosinated
tubulin levels were not changed in any conditions.
Next, we performed an endothelial barrier permeability assay.
HUVEC cells were seeded on 3 mm pore membrane inserts and
grown to form confluent monolayers. DMXAA or CA4 were
added, along with fluorescently labeled 3 k dextran, to the upper
chamber and medium was collected from the lower chamber at
each time point. Data are reported as lower chamber fluorescence
intensity was divided by upper chamber intensity (Fig. 3F). CA4
treatment strongly increased dextran barrier crossing, while
DMXAA had no effect compared to control treatment.
Finally, we performed in vitro polymerization assays with pure
tubulin in the presence of drugs to further test the possibility that
DMXAA directly destabilizes microtubule (Fig. 4). In brief, pure
tubulin derived from bovine brain, containing a small fraction of
subunits covalently labeled with a fluorescent dye, was mixed with
or without drug in GTP containing polymerization buffer.
Samples were incubated at 37uC for 10 to 20 min to polymerize
microtubule, then fixed and imaged. This assay scores for effects
on both nucleation and elongation of microtubules, and the
tubulin concentration was adjusted to the minimal value needed to
observe polymerization, to maximize the sensitivity of the assay to
potential inhibitors. As shown in fig. 4A, CA4 completely blocked
microtubule polymerization, while DMXAA did not show any
significant inhibition. It is important to compare the effect of each
drug to that of its vehicle, which was water for DMXAA (dissolved
as its sodium salt) and DMSO for CA4, since DMSO alone
promotes microtubule polymerization. The total number of
microtubules and their length were manually quantified using
ImageJ (fig. 4 B and C). In order to represent the distribution of
the microtubule lengths obtained from many dozens of measure-
ments, we fit a two-parameter Weibull probability density function
using MATLAB implementation. DMXAA has little effect on total
microtubule number per field (Fig. 4B), but consistently caused
a modest shift in the length distribution towards a higher fraction
of long microtubules (Fig. 4C). Overall the effect of DMXAA on
pure tubulin polymerization was very mild, and if anything there
was a slight increase in polymerization, unlike the complete
inhibition caused by CA4.
Discussion
In this study, we directly compared the effect of representative
agents from the two main classes of VDA drugs on endothelial
cells. Such a head-to-head, quantitative comparison is, to our
knowledge, missing from the literature. We felt it was important
because of some hints in the literature that flavonoid-class drugs
cause mitotic arrest or disrupt the endothelial cell cytoskeleton.
Using time-lapse microscopy, immuno-staining, soluble tubulin
extraction assays and endothelial cell permeability assays we
confirmed that CA4 depolymerizes microtubules at low concen-
trations, which leads to an increased fraction of polymerized actin,
cell retraction, loss of endothelial barrier function and eventual
mitotic arrest of HUVECs. DMXAA had none of these effects,
confirming the widely held view that it acts in an entirely different
way. The microtubule polymerization assay (fig. 4) showed that
there might be mild positive effects of DMXAA on tubulin
polymerization as overall tubulin polymer sizes were longer in the
presence of DMXAA. This result suggests that DMXAA might
stabilize microtubules. However, as shown in fig. 1, there is no
cell area for each time point was normalized by time point 0. At each condition, Cell surface areas were averaged from at least 3 different stage
positions. Error bars were calculated as the standard deviation from the results of 3 independent experiments. (C) Images were collected from phase
contrast time-lapse movies at 12 hours after drug treatment. Asynchronously grown cells were treated with 500 mM of DMXAA, 100 nM of CA4 or
without drug (control). (D) From the time-lapse image, mitotic cells were counted after 12 hours of drug treatment. At least 200 cells from 3 different
stage positions were counted at each condition. Error bars were calculated as the standard deviation from the results of 3 independent experiments.
doi:10.1371/journal.pone.0040177.g001
Figure 2. DMXAA did not disturb microtubule or actin
structure. Cells were treated with serial dilutions of DMXAA for
30 min and CA4 for 10 min. Immuno-staining was performed using
anti-DM1alpha and rhodamine-phalloidine to visualize microtubule and
actin respectively. Microtubules are shown in green and actin in red.
Nuclei were stained using DAPI (blue). The white bar indicated 20 mm.
doi:10.1371/journal.pone.0040177.g002
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PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e40177Figure 3. Quantitative analysis of the polymerization state of microtubules and actin in drug treated cells. (A) Soluble tubulin
extraction assays were performed after treatment with serial dilutions of CA4 for 10 min. Tubulin and actin monomers were extracted from
supernatant but polymerized tubulin and actin remained in the pellets. Each supernatant and pellet was subject to Western blotting to measure
protein levels of tubulin and actin. The ratio of soluble vs. polymerized tubulin and actin are plotted in the lower panel. Error bars were calculated as
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for perturbation of microtubule dynamic. Thus it is unclear that
the mild effect of DMXAA on pure tubulin is physiologically
significant. In any case it goes, if anything, in the opposite
direction compared to CA4.
Our data leave open the question of whether DMXAA has any
action on endothelial cells that are related to its VDA action in vivo.
Baguley’s group showed that high concentration of DMXAA
(400 mg/ml) increased endothelial cell death by an unknown
pathway in the murine endothelial cell, HECPP [19]. Also while
we revised this manuscript, Lou group reported that DMXAA
induced rapid morphological changes and actin reorganization via
p38 pathway in HUVEC cells [29]. At the moment, we do not
have explanation why we got opposite results with Lou group. We
know our DMXAA is fully active, based on its effects on TNF-
alpha secretion from Raw264.7 cells (Fig. 3G). Although we could
not find how Lou group dissolved DMXAA in their paper, this
could be important point. The only effects of DMXAA that we
observed on endothelial cells were a mild decrease in the fraction
of actin in polymer (fig. 3) and a mild decrease in HUVEC
proliferation rate, manifest by lower mitotic index and also in
24 hr growth assays (not shown). Both effects were only seen at
high DMXAA concentrations (250–500 mM). We noted similar or
stronger growth inhibition in cancer cell lines (HeLa, A549) and
Raw264.7 cells by DMXAA (data not shown), so these effects are
probably not endothelium specific. We definitely did not observe
a strong increase in apoptosis by time-lapse imaging (not shown).
Whether these relatively mild effects at high DMXAA concentra-
the standard deviation from the results of 4 independent experiments. (B) DMXAA was treated in serial dilution for 30 min. The same experiment was
performed as in (A). (C) Cells were pretreated with 300 nM of Taxol for 30 min before CA4 treatment. And soluble tubulin and actin extraction assay
was performed as (A and B). (D) Various microtubule targeting drugs were treated as indicated time for 15 min and followed by soluble tubulin and
actin extraction assay. And only pellets in each condition were subjected to detect polymerized actin or tubulin. (E) Cells were treated with CA4,
DMXAA or Taxol as indicated concentrations and total cell lysates were analyzed by western blotting. (F) HUVEC monolayer permeability assay. Cells
were grown on 3 mm pore membrane inserts for 2 days and DTAF labeled 3 k dextran (50 mg/ml) was added in insert with or without drug (control).
Fluorescence intensity of the lower chamber was measured to analyze the permeability of the monolayer. The percent of released dextran was
plotted as the fluorescence intensity of the lower chamber relative to the fluorescence intensity of the upper chamber intensity. (G) TNF-alpha ELISA
assay. Media were collected after DMXAA treatment for various time and concentration for TNF-alpha ELISA assay. Error bars were calculated as the
standard deviation from the results of 5 independent experiments.
doi:10.1371/journal.pone.0040177.g003
Figure 4. Comparison of the effects of CA4 and DMXAA on tubulin polymerization. Polymerized tubulin was visible by fluorescence
microscopy as string like shapes. Various concentrations of DMXAA and its vehicle control (water) showed similar tubulin polymerization rates. DMSO
was used as a positive control. The white scale bar indicates 20 mm. All images were taken after 20 min polymerization. (B) The number of polymers
per field were counted using ImageJ. Three to ten different random stage positions were counted to measure number of polymers for each
condition, except for DMSO treated were one stage position was counted. Error bars were calculated as the standard deviation from the results of 3
independent experiments. (C) The Weibull-parametrized distribution of microtubule length compared across conditions in 20 min polymerization
samples. The lengths were measured using ImageJ and fit to a Weibull probability density function for each condition.
doi:10.1371/journal.pone.0040177.g004
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activity is unclear. In terms of effect on cell physiology that seem
much less impressive than the cytokine secretion promoting
activity of DMXAA on leukocytes.
Taken together, or results suggest that DMXAA had little or no
effect on the morphology, cytoskeleton or barrier function of
cultured endothelial cells. This supports the standard literature
assumption that the two classes of VDA work by fundamentally
different mechanisms, and provides the first quantitative evidence
(to our knowledge) that DMXAA lacks anti-microtubule effects.
We did detect some mild effects of DMXAA in our assays, but
only at the highest concentrations. It exhibited mild anti-pro-
liferative activity on HUVECs as assayed by decreased mitotic
index, mild decrease in actin polymer on HUVECs, and mild
stabilization of microtubules in a pure tubulin assay. We doubt
that the in vitro effect on microtubules is physiologically significant
given the lack of mitotic arrest and the lack of evidence for
microtubule stabilization in vivo.
In conclusion, we our data bring strong new evidence in support
of the widely-held literature assumption that DMXAA does not
act via microtubule destabilization like CA4. So how and which
cytokines regulate endothelial hyper-permeability would be an
important question to be addressed in the future.
Materials and Methods
Cell culture and reagents
Human umbilical vein endothelial cells (HUVECs) were
purchased from LONZA (Walkersville, MD, USA). Cells were
maintained using EGM-2 Bullet kit (LONZA, Walkersville, MD,
USA) in a humidified incubator (37uC, 5% CO2). For experi-
ments, cells were seeded on fibronectin (50 mg/ml) (Sigma-
Aldrich, St Louis, MO, USA) coated dishes. Raw264.7 cells were
purchased from ATCC (Manassas, VA, USA). Cells were grown
in DMEM medium (Cellgro Mediatech, Manassas, VA, USA)
supplemented with 10% heat inactivated FBS (Gibco, Grand
Island, NY, US). DMXAA was purchased from Wuhan Sunrise
Technology (Wujiashan, Wuhan, China) and CA4 was from
Sigma (Sigma, St Louis, MO, USA). DMXAA was dissolved in
equimolar sodium bicarbonate buffer overnight and lyophilized to
make DMXAA sodium salt. For experiments, DMXAA sodium
salt was dissolved in water at 50 mM stock concentration and
diluted using culture medium to the desired concentration. CA4
was dissolved in DMSO.
Time-lapse imaging and image analysis
Cells were grown on fibronectin coated 24 well glass bottom
dishes (No. 1.5) (MatTek Corporation, Ashland, MA, US). Plates
were mounted on a Prior Proscan II motorized stage in a custom-
built microscope incubator (HMS machine shop) maintained at
37uC and 5% CO2. A layer of mineral oil on top of the cell culture
media was used to prevent evaporation. All images were collected
with a TE2000E motorized inverted microscope (Nikon Instru-
ments, Melville, NY, US) using phase contrast. Images were
acquired with a Hamamatsu ORCA ER cooled CCD camera
(Hamamatsu Photonics, Bridgewater, NJ) controlled with Meta-
Morph 7 software (Molecular Devices, Inc., Sunnyvale, CA, US).
For time-lapse experiments, images were collected every 30 sec-
onds for cell surface area analysis or 5 minutes for mitotic index
analysis, using an exposure time of 50 ms and 262 binning. For
cell surface analysis, each individual cell was outlined to measure
number of pixels within the cell using image J and cell surface
areas were calculated by sum of number of pixels of all cells at
each time points. Relative cell surface areas against time 0 were
plotted.
Immunofluorescence and confocal miscrscopy
Cells were grown on No. 1.5 coverslips for one day and treated
with DMXAA for 30 min or CA4 for 10 min and fixed using 4%
formaldehyde (Polysciences, Inc., Warrington, PA, US) in CBS
buffer (10 mM MES (pH 6.1), 138 mM KCl, 3 mM Mgcl2,
2 mM EGTA). Fixed cells were permeablized using 0.5% of
tritonX-100 (Sigma, St Louis, MO, US) in TBS for 10 min and
then blocked and incubated with AbDil (0.1% tristonX-100 and
2% BSA in TBS). Microtubules and actin were visualized using
FITC tagged DM 1-alpha antibody (Sigma, St Louis, MO, US)
and phalloidin-TRITC (Sigma, St Louis, MO, US) respectively.
Nuclei were stained using DAPI (Sigma, St Louis, MO, US).
Fluorescence images were collected by Nikon TE2000U inverted
microscope with Nikon 1.4 NA DIC optics, 60X oil immersion
objective (Nikon, Meville, NY). Confocal images were obtained
using, Yokogawa CSU-10 spinning disk confocal head (Yokogawa
Corporation of America, Newnan, GA, USA) with Sutter emission
filter wheel. Images were acquired with Hamamatsu ORCA-AG
cooled CCD camera (Hamamatsu, Hamamatsu, Japan) controlled
with MetaMorph 7 software (Universal Imaging, Molecular
Devices, Sunnyvale, CA).
Soluble tubulin and actin extraction assay
Cells were incubated with tubulin extraction buffer (60 mM
PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, 0.5%
tritonX-100 and 10 mg/ml of taxol) containing protease inhibitor
(Roche Diagnostics, Indianapolis, IN, USA) for 2 min. Superna-
tant was collected for the soluble fraction and the remaining
adherent cells were harvested for the polymerized fraction. Both
fractions were lysed using Western blot sample buffer (Invitrogen,
Grand Island, NY, US) and an equal volume of each fraction was
subjected to Western blotting.
Western blot
Cells were lysed using 1X protein sample buffer (Invitrogen,
Grand Island, NY, US)and. separated by SDS PAGE. Protein was
transferred to nitrocellulose membrane (pore size 0.2 mm). Both
anti-alpha tubulin and anti-beta actin antibodies were purchased
from Sigma (St Louis, MO, USA).
Endothelial permeability assay
HUVECs were plated onto fibronectin coated BD BioCoat
3 mm pore inserts (BD Biosciences, Franklin Lakes, NJ, US) and
grown until confluent. Drugs were added to the upper chamber
with DTAF tagged 3 k dextran (60 mg/ml) (Sigma, St Louis, MO,
USA). At each time point, the lower chamber media was collected
and analyzed in a Victor multilabel plate reader (PerkinElmer,
Waltham, MA, US).
Tubulin polymerization assay
Tubulin polymerization assays were performed as previously
described [31]. Briefly, labeled and unlabeled tubulin were mixed
at a ratio of 5:1 to a final concentration of 30 mM in 2 mM GTP
containing BRB80 buffer (80 mM K PIPES (pH 6.8), 1 mM
MgCl2, 1 mM EGTA). This mix was incubated at 37uC and 2 ml
aliquots of each condition were taken at 10 min and 20 min.
Aliquots were diluted into fixation buffer (60% glycerol, 0.1%
glutaraldehyde in BRB80 buffer) and gently inverted 5 times. This
mixture was placed on a glass slide, covered with 22 by 22 mm
coverslip and observed with a fluorescence microscope. The
Vascular Disrupting Agents Effect on Cytoskeleton
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e40177number and the lengths of polymerized microtubules were
analyzed using ImageJ.
TNF-alpha ELISA assay
Raw264.7 was seeded on 96 well plate at a density of 2610
5 per
ml. Cells were treated with DMXAA for various time. And media
were collected for TNF-alpha ELISA assay. TNF-alpha ELISA
assay (Biolegend, San Diego, CA, USA) was performed as
manufacturer’s recommendation.
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